Curis, Inc. (CRIS): Price and Financial Metrics


Curis, Inc. (CRIS)

Today's Latest Price: $0.82 USD

0.00 (-0.55%)

Updated Jun 2 9:44am

Add CRIS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

CRIS Stock Summary

  • The ratio of debt to operating expenses for Curis Inc is higher than it is for about merely 0.32% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -1.26 for Curis Inc; that's greater than it is for just 5.24% of US stocks.
  • With a year-over-year growth in debt of -100%, Curis Inc's debt growth rate surpasses only 0% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Curis Inc are MVIS, NOVN, EVGN, CDTX, and ORMP.
  • CRIS's SEC filings can be seen here. And to visit Curis Inc's official web site, go to www.curis.com.
CRIS Daily Price Range
CRIS 52-Week Price Range

CRIS Stock Price Chart More Charts


CRIS Price/Volume Stats

Current price $0.82 52-week high $2.90
Prev. close $0.83 52-week low $0.62
Day low $0.82 Volume 2,679
Day high $0.82 Avg. volume 169,597
50-day MA $0.78 Dividend yield N/A
200-day MA $1.49 Market Cap 30.18M

Curis, Inc. (CRIS) Company Bio


Curis, Inc. engages in the discovery and development of drug candidates for the treatment of human cancers. The company was founded in 2000 and is based in Lexington, Massachusetts.


CRIS Latest News Stream


Event/TimeNews Detail
Loading, please wait...

CRIS Latest Social Stream


Loading social stream, please wait...

View Full CRIS Social Stream

Latest CRIS News From Around the Web

Below are the latest news stories about Curis Inc that investors may wish to consider to help them evaluate CRIS as an investment opportunity.

Curis Reports First Quarter 2020 Financial Results

LEXINGTON, Mass. , May 12, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS ), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2020 . "The first quarter of 2020 was productive for Curis, as we advanced our ongoing study for CA-4948 and accomplished several key licensing and financial objectives to support future progress across our pipeline and business," said James Dentzer , President and Chief Executive Officer of Curis. "In response to the COVID-19 pandemic, we have implemented both clinical and operational measures to help protect patients, staff, study investigators and our community, and I am incredibly proud of the resiliency and dedication our team ...

Benzinga Feeds | May 12, 2020

Curis to Release First Quarter 2020 Financial Results and Hold Conference Call on May 12, 2020

LEXINGTON, Mass., May 5, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2020 financial results on Tuesday, May 12,…

PR Newswire | May 5, 2020

Edited Transcript of CRIS earnings conference call or presentation 19-Mar-20 8:30pm GMT

Q4 2019 Curis Inc Earnings Call

Yahoo | April 13, 2020

Curis to Present at 19th Annual Needham Virtual Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2020 at 12:00 p.m. ET.

Yahoo | April 7, 2020

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2020, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 110,000 shares of Curis common stock to three new employees, with a grant date of April 1, 2020 (the "Q2 2020 Inducement Grants").

Yahoo | April 3, 2020

Read More 'CRIS' Stories Here

CRIS Price Returns

1-mo -3.53%
3-mo -35.43%
6-mo -55.43%
1-year -42.66%
3-year -91.41%
5-year -95.19%
YTD -51.76%
2019 146.38%
2018 -80.29%
2017 -77.27%
2016 5.84%
2015 94.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9912 seconds.